Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Despite the considerable use of oral steroids in the regular management of benign vocal fold lesions there is little evidence base in the literature. This study will investigate the efficacy of oral steroids for the treatment of vocal fold lesions in a controlled manner. The specific aim of this study is to determine the effectiveness of of a short course of oral steroids prior to behavioral voice therapy in patients with benign, phonotraumatic vocal fold lesions. Enrolled subjects will be randomized using a random numbers table to either receive oral steroids or no steroids prior to the initiation of voice therapy. The therapist and individuals involved in the collection and analysis of data will be blinded as to whether the subject received drug. Prior to initiation of therapy subjects will be asked to return for an interval evaluation during which they undergo videostroboscopy and voice evaluation. Subjects will enter then the voice therapy phase . After an initial evaluation to determine the best mode of therapy they will receive a behavioral voice therapy course, which includes a range of behavioral modifications and motor learning techniques, along with lifestyle measures. In all these phases acoustic and aerodynamic measurements will be collected as well as audio-visual material from the videostroboscopic exams. The investigators hypothesize that oral steroids will lead to a reduction in lesion size, which will substantially aid in the delivery and incorporation of voice therapy techniques, contributing to the improvement of overall laryngeal biomechanics and providing an ideal starting point for behavioral voice therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health

Criteria

Inclusion Criteria:

• Age 18-80 males and females

• Presence of phonotraumatic lesion deemed to be etiologic for the complaint of dysphonia

• Voice therapy deemed to be the primary (or at least initial) treatment to address the dysphonia.

• Willingness to be an active participant in voice therapy.

Exclusion Criteria:

• Use of any glucocorticoids (oral, inhaled, or intravenous) within 3 months of the initial evaluation

• Known allergy or hypersensitivity to oral steroids

• Active infection

• Diabetes Mellitus

• Prior history of radiation to the neck

• Recent myocardial infarction

• Recent gastrointestinal surgery with bowel anastamosis (3 months)

• Active peptic ulcer

• Pregnancy

• Severe depression or history of psycosis

• History of recent laryngeal surgery (within 12 months)